Earnings call transcript: Natura & Co Q1 2026 EPS beats expectations but stock falls

Natura & Co reported Q1 2026 EPS of $0.136 versus $0.082 expected, a 65.9% beat, but revenue missed at $4.75B versus $4.8B consensus and the stock fell 7.3% after hours to $9.91. Revenue declined 7.7% in BRL and 3.7% in constant currency, with Brazil down 5.5% and Hispana down 1.1%, while reported EBITDA margin was 7.3% and net loss widened to BRL 445M. Management said restructuring benefits will start showing in Q2, but near-term risks remain from Argentina, Brazil, FX, and a pending SAP system transition.

Analysis

The market is pricing the quarter on the wrong line item. The profit beat was mostly a sequencing artifact from cost cuts landing before top-line normalization; that makes the next two quarters more important than the current one because the restructuring math is front-loaded while demand recovery is still aspirational. The key second-order effect is that a leaner SG&A base can temporarily mask weak sell-in, but if consultant inventory and channel activity don’t re-accelerate, operating leverage turns negative again once the one-offs roll off.

The real read-through is for Brazil consumer-discretionary peers and any supplier exposed to direct selling channels. If Natura’s channel stabilization is real, it should show up first as improved replenishment order cadence, then as better factory absorption and lower working-capital drag; that would be a tailwind for logistics, packaging, and select local consumer names with overlapping lower-income exposure. If it is not real, the likely victims are franchise/beauty peers that are also leaning on promotional intensity, because Natura will be forced to buy growth with incentives rather than brand momentum.

The biggest hidden risk is the June systems transition layered on top of a still-fragile channel. That creates a classic “good quarter / bad setup” pattern: the market may initially give credit for margin repair, but any operational hiccup could trigger another de-rating because the stock is already near stress levels and balance-sheet flexibility is being consumed by non-recurring items. On the upside, if Q2 shows even modest revenue inflection plus lower severance, the stock could re-rate sharply from deeply pessimistic levels, but that requires evidence within 30-60 days, not at year-end.

Consensus seems to be underestimating how much of the 2026 story depends on execution quality rather than macro beta. The company can still hit its margin framing even with mediocre demand if the new model and working-capital discipline hold, so the better trade is to separate operational repair from top-line recovery. This is a name where the first derivative matters more than the absolute level: a small sequential improvement in sell-out and consultant activity would have an outsized impact on sentiment because expectations are already compressed.

Key Decisions for Investors

• Avoid chasing the post-earnings bounce; wait 2-4 weeks for evidence that Q2 replenishment and consultant activity are improving before taking any long in Natura-linked equities.
• If we want exposure to a turn in Brazilian consumer/beauty execution, prefer a pair: long a higher-quality local consumer name with cleaner operating leverage, short NATU3/Natura-linked exposure into the June SAP risk window.
• Buy short-dated downside protection on Natura around the early-June systems cutover; the setup is asymmetrically vulnerable to an operational miss even if the medium-term thesis remains intact.
• For multi-strategy books, treat this as a catalyst-driven trade, not an investment: size any long only after a Q2 revenue inflection, with a 30-45 day stop if sell-in does not follow sell-out.
• Use the weakness to screen for beneficiaries of channel normalization and inventory rebuild in Brazil, rather than assuming broad consumer demand is fixed; the second-order winner is likely logistics/fulfillment or select local suppliers, not the branded retailer itself.